TP化疗方案联合曲妥珠单抗治疗HER2阳性乳腺癌的临床价值研究  

The Clinical Value of TP Chemotherapy Combined with Trastuzumab in the Treatment of HER2 Positive Breast Cancer

作　　者：吴艳丽 聂桦 WU Yanli;NIE Hua(Department of Oncology,NO.1 Peoples Hospital of Guangshui,Guangshui,Hubei,432700,China)

机构地区：[1]广水市第一人民医院肿瘤科,湖北广水432700

出　　处：《中外医疗》2024年第33期93-96,共4页China & Foreign Medical Treatment

摘　　要：目的 分析研究TP化疗方案联合曲妥珠单抗治疗HER2阳性乳腺癌的价值。方法 方便选取2020年1月—2022年12月广水市第一人民医院收治的58例HER2阳性乳腺癌患者为研究对象。按照不同治疗药物分组,每组29例。常规治疗组仅接受TP化疗,联合治疗组接受TP化疗+曲妥珠单抗治疗。比较两组患者化疗前后的血清肿瘤标志物水平[癌胚抗原(carcinoembryonic antigen,CEA)、糖蛋白153(carbohydrate antinegen153,CA153)],生命质量评分,化疗总有效率及化疗期间的不良反应发生率。结果 两组患者化疗前的血清肿瘤标志物水平、乳腺癌患者生命质量测定量表(Functional Assessment of Cancer TheraPy-Breast,FACT-B)比较,差异无统计学意义(P均>0.05)。化疗后,联合治疗组患者的CEA(5.17±2.07)ng/mL、CA153水平(27.28±4.31)IU/mL均低于常规治疗组的(7.42±3.44)ng/mL、(34.51±5.79)IU/mL,差异有统计学意义(t=3.107,5.394;P均<0.05)。化疗后,联合治疗组FACT-B评分、化疗总有效率均高于常规治疗组,差异有统计学意义(P均<0.05)。两组患者化疗期间的不良反应发生率比较,差异无统计学意义(P>0.05)。结论 基于TP化疗方案联合曲妥珠单抗对HER2阳性乳腺癌患者进行治疗能够有效提高化疗效果,改善血清肿瘤标志物水平,同时安全性较高。Objective To analyze the value of TP chemotherapy regimen combined with trastuzumab in the treatment of HER2 positive breast cancer.Methods A total of 58 patients with HER2-positive breast cancer admitted to the NO.1 People's Hospital of Guangshui from January 2020 to December 2022 were conveniently selected as the study subjects.According to different treatment drugs,29 cases in each group.The conventional treatment group received TP chemotherapy alone,and the combined treatment group received TP chemotherapy + trastuzumab.The serum tumor marker levels [carcinoembryonic antigen(CEA),carbohydrate antinegen 153(CA153)],quality of life score,the total effective rate of chemotherapy and the incidence of adverse reactions during chemotherapy were compared between the two groups before and after chemotherapy.Results There was no significant difference in serum tumor markers and Functional Assessment of Cancer TheraPy-Breast(FACT-B) between the two groups before chemotherapy(both P>0.05).After chemotherapy,the levels of CEA(5.17±2.07) ng/mL and CA153(27.28±4.31) IU/mL in the combined treatment group were lower than those in the conventional treatment group(7.42±3.44) ng/mL,(34.51±5.79) IU/mL,the differences were statistically significant(t=3.107,5.394;both P<0.05).After chemotherapy,the FACT-B score and the total effective rate of chemotherapy in the combined treatment group were higher than those in the conventional treatment group,and the differences were statistically significant(both P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during chemotherapy(P>0.05).Conclusion The treatment of HER2-positive breast cancer patients based on TP chemotherapy combined with trastuzumab can effectively improve the efficiency of chemotherapy,improve the level of serum tumor markers,and have high safety.

关 键 词：曲妥珠单抗 乳腺癌 化疗 临床疗效 紫杉醇 

分 类 号：R737.9[医药卫生—肿瘤]